Prescription pattern of drugs in post-COVID-19 mucormycosis patients in Government General Hospital, Kakinada – A retrospective study

Abstract

Abstract: INTRODUCTION: Mucormycosis, or zygomycosis, is an aggressive fungal infection caused by Mucorales, posing a significant threat, particularly to immunocompromised individuals. Its incidence has surged in the context of the COVID-19 pandemic, necessitating a deeper understanding of its management strategies. MATERIALS AND METHODS: This retrospective cross-sectional study analyzed prescription patterns for post-COVID-19 mucormycosis in a tertiary care hospital. Medical records of 108 patients diagnosed with post-COVID-19 mucormycosis were reviewed to extract relevant data. RESULTS: The study revealed notable patterns in prescription management, including a male predominance (78.3%) and a mean age of 52.41 years. Diabetes mellitus was prevalent (95%), emphasizing its association with mucormycosis. Antifungal therapy, primarily posaconazole (95%), and adjunctive treatments varied. Surgical intervention, particularly debridement (70%), was crucial. Analgesic therapy, notably diclofenac (52%), and other medications were commonly prescribed, reflecting the complex health-care needs of mucormycosis patients. CONCLUSION: The study provides valuable insights into prescription patterns in post-COVID-19 mucormycosis, emphasizing the need for tailored approaches to optimize outcomes in this vulnerable patient population. Understanding prescription patterns for post-COVID-19 mucormycosis is vital for guiding clinical decision-making and optimizing treatment strategies in this vulnerable patient population. Further research is warranted to address limitations and enhance patient care and outcomes.